Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer

AKDOĞAN O., Sutcuoglu O., Ogut B., Akyurek N., Ozdemir N., Ozet A., ...Daha Fazla

IMMUNOTHERAPY, cilt.14, sa.14, ss.1121-1131, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 14
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/imt-2021-0338
  • Dergi Adı: IMMUNOTHERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1121-1131
  • Anahtar Kelimeler: biomarker, chemotherapy, immunotherapy, molecular oncology, PD-L1, radiotherapy, VISTA, IMMUNE-MECHANISMS, ADENOCARCINOMA, CHECKPOINT, NIVOLUMAB, RADIATION, DOCETAXEL
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: PD-L1 and VISTA are important checkpoint control stations and play an immunomodulatory role in patients with non-small-cell lung cancer. Method: The expression levels of PD-L1 and VISTA between pre- and post-treatment tumor tissue were compared. Results: While PD-L1 expression was >1% in 35% of patients before neoadjuvant therapy, PD-L1 expression was >1% in 65% of patients after treatment (p = 0.004). VISTA expression was >1% in 41% of patients before treatment, and this rate was 65% after treatment (p = 0.025). Conclusion: Chemotherapy and chemoradiotherapy can be used as immunizers by increasing PD-L1 and VISTA expression levels.